uploads/2018/05/Alecensa.png

Roche’s Alecensa, Esbriet, Gazyva, and Erivedge in Q1 2018

By

Updated

Alecensa revenue trends

In the first quarter, Roche’s (RHHBY) Alecensa generated revenues of 119 Swiss francs compared to 68 million Swiss francs in the first quarter of 2017, which reflected ~75% growth on a YoY (year-over-year) basis and 1% growth sequentially.

In the first quarter, in the United States, Europe, and Japan, Alecenca generated revenues of 56 million Swiss francs, 17 million Swiss francs, and 37 million Swiss francs, respectively.

Alecensa is used to treat individuals with metastatic non-small cell lung cancer with anaplastic lymphoma kinase (or ALK) gene expression. In the marketplace, Alecensa’s peers include Novartis’s (NVS) Zykadia, Pfizer’s (PFE) Xalkori, and Takeda Pharmaceutical’s (TKPYY) Alunbrig.

Article continues below advertisement

Esbriet’s revenue trends

In the first quarter, Esbriet reported revenues of 222 million Swiss francs compared to 202 million in the first quarter of 2017, which reflected ~10% YoY growth and a 4% decline sequentially.

In the first quarter, in the US and European markets, Esbriet reported revenues of 155 million Swiss francs and 56 million Swiss francs, respectively. Esbriet is used in the treatment of idiopathic pulmonary fibrosis.

Gazyva/Gazyvaro revenue trends

In the first quarter, Gazyva/Gazyvaro reported revenues of 84 million Swiss francs, which reflected ~27% YoY growth. In the first quarter, in the US and Europe markets, Gazyva/Gazyvaro generated revenues of 43 million Swiss francs and 29 million Swiss francs, respectively. Gazyva is used in the treatment of chronic lymphoblastic leukemia and follicular lymphoma.

Erivedge and Cotellic revenue trends

Erivedge reported revenues of 61 million Swiss francs in the first quarter, which is ~6% YoY growth. In the first quarter, in the US and Europe markets, Erivedge generated revenues of 36 million Swiss francs and 19 million Swiss francs, respectively. Erivedge finds its use in the treatment of individuals with basal cell carcinoma.

In the first quarter, Cotellic reported revenues of 15 million Swiss francs, which included revenues of 4 million Swiss francs and 9 million Swiss francs from the US and Europe markets, respectively. Cotellic is used in combination with Zelboraf for the treatment of metastatic melanoma with a BRAF V600E/V600K mutation.

In May, Roche announced that its phase 3 IMblaze 370 trial, which was evaluating Tecentriq in combination with Cotellic compared to regorafenib for the treatment of advanced colorectal cancer, didn’t meet its primary endpoint of overall survival.

Advertisement

More From Market Realist